1. Home
  2. GAU vs IVA Comparison

GAU vs IVA Comparison

Compare GAU & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

HOLD

Current Price

$3.00

Market Cap

680.7M

Sector

N/A

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$6.21

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAU
IVA
Founded
1999
2011
Country
Canada
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
680.7M
1.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GAU
IVA
Price
$3.00
$6.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$3.00
$16.20
AVG Volume (30 Days)
3.9M
566.7K
Earning Date
02-12-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$328,443,000.00
$19,929,536.00
Revenue This Year
$82.50
N/A
Revenue Next Year
$57.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
57.74
N/A
52 Week Low
$1.00
$2.40
52 Week High
$3.26
$7.98

Technical Indicators

Market Signals
Indicator
GAU
IVA
Relative Strength Index (RSI) 55.26 54.80
Support Level $2.68 $5.97
Resistance Level $3.15 $6.37
Average True Range (ATR) 0.23 0.31
MACD 0.00 -0.08
Stochastic Oscillator 72.94 30.87

Price Performance

Historical Comparison
GAU
IVA

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: